glp-1 dementia improves the neuronal supportive ability of astrocytes in Alzheimer's disease by regulating mitochondrial dysfunction via the cAMP/PKA pathway Dementia: Could GLP1 Receptor Agonists
Description
Bolli GB, Owens DR (2014) Lixisenatide, a novel GLP-1 receptor agonist

While it's designed for long-term use, it's always best to consult a healthcare professional to ensure it's the right choice for your health and weight management goals

The acylation technique with fatty acids, well established in diabetes therapeutics, extends the biological half-life of the peptide by facilitating albumin binding

Hims' clinical structure relies on licensed physicians reviewing patient health history and determining medication eligibility

More than half a billion people are living with diabetes worldwide and it is estimated that by 2045 there will be 693 million people diagnosed with the condition [1]

As headlines tout possible cognitive benefits, many patients and clinicians are asking: Can GLP1 drugs lower dementia risk
